The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison Study.
Stefan FlascheMark JitIsabel Rodríguez-BarraquerLaurent CoudevilleMario ReckerKatia KoelleGeorge MilneThomas J HladishT Alex PerkinsDerek A T CummingsIlaria DorigattiDaniel J LaydonGuido EspañaJoel K KelsoIra LonginiJose LourencoCarl A B PearsonRobert C ReinerLuis Mier-Y-Terán-RomeroKirsten VanniceNeil M FergusonPublished in: PLoS medicine (2016)
Dengvaxia has the potential to reduce the burden of dengue disease in areas of moderate to high dengue endemicity. However, the potential risks of vaccination in areas with limited exposure to dengue as well as the local costs and benefits of routine vaccination are important considerations for the inclusion of Dengvaxia into existing immunisation programmes. These results were important inputs into WHO global policy for use of this licensed dengue vaccine.